References
- Jacobson IM, McHutchison JG, Dusheiko GM et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med.364, 2405–2416 (2011).
- Sherman KE, Flamm SL, Afdhal NH et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study. Hepatology52(Suppl.), 401A (2010).
- Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med.364, 2417–2428 (2011).
- Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med.364, 1195–1206 (2011).
- Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med.364, 1207–1217 (2011).
- Bartenschlager R, Lohman V. Replication of hepatitis C virus. J. Gen Virol.81, 1631–1648 (2000).
- Ozeki I. Safety and antiviral activity of a monotherapy with a mp-424 for 24 weeks in naive patients with chronic hepatitis C virus genotype 1b infection. J. Hepatol.50, S350 (2009).
- McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med.360, 1827–1838 (2009).
- Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet.376, 705–716 (2010).
- Treviño A, de Mendoza C, Parra P et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV–HCV-coinfected patients. Antivir. Ther.16(3), 413–416 (2011).
- Sulkowski M, Dieterich D, Sherman K et al. Interim analysis of a Phase 2a double-blind study of TVR in combination with pegIFN-a2a and RBV in HIV/HCV co-infected patients. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011 (Abstract 146LB).
- Kasserra C, Hughes E, Treitel M et al. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011 (Abstract 118).
- van Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February–2 March 2011 (Abstract 119).